ADVANCING THERAPIES TO TRANSFORM THE TREATMENT OF inflammatory and immunologic diseases

RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise in immunology, we are developing novel molecules that are designed to modulate the critical immune responses underlying these diseases.

A PIPELINE INTENT ON IMPROVING COUNTLESS LIVES

†RAPT owns ex-China rights including US, Europe, and Japan, Jemincare owns China, Taiwan, Hong Kong and Macau
*Regional collaboration and license with Hanmi in Korea, Taiwan and China (including Hong Kong and Macau). We are seeking a partner to further develop tivumecirnon outside the Hanmi Territory.

RPT904, a long-acting anti-IgE antibody for allergic inflammatory diseases

Next generation CCR4 antagonist for Th2-driven disorders

Tivumecirnon, an oral CCR4 antagonist for oncology

ADVANCING THERAPIES TO TRANSFORM THE TREATMENT OF inflammatory and immunologic diseases

A PIPELINE INTENT ON IMPROVING COUNTLESS LIVES

READ MORE